Search results for "urea"

showing 10 items of 888 documents

The vascular flora of Nature Reserve “Pizzo Cane, Pizzo Trigna and Grotta Mazzamuto” (NW Sicily)

2009

A floristic investigation was carried out in “Pizzo Cane, Pizzo Trigna and Grotta Mazzamuto” Nature Reserve, one of the largest in Sicily. In spite of the considerable botanical interest of this area, few data were available from classic and recent literature. Based on field investigations, coupled with bibliographic and herbarium researches, we have listed 951 infrageneric taxa belonging to 103 families and 446 genera. A lot of these entities are reported in this area for the first time, for others ancient records are confirmed. Life form analysis shows the dominance of therophytes (44,79%) and hemicryptophytes (27,77%). From a chorological point of view, Mediterranean elements show a grea…

Nature reserveFloraEcologybiologyendemism floristic biodiversity phytogeography Nature reserve SicilyEcologySettore BIO/02 - Botanica SistematicaPlant SciencePhytogeographybiology.organism_classificationFloristicsHerbariumCentaureaEryngiumEndemismEcology Evolution Behavior and SystematicsWebbia
researchProduct

Uridine uptake inhibition as a cytotoxicity test for a human hepatoma cell line (HepG2 cells): comparison with the neutral red assay

2001

International audience; This study describes a sensitive microassay for measuring cytotoxicity based on the degree of inhibition of RNA synthesis in HepG2 cells. RNA synthesis is measured by the kinetic uptake of radiolabeled uridine. A large number of compounds were tested in a wide range of concentrations. The concentration required to induce 50% inhibition of HepG2 uridine uptake rates (IC50) was determined for each compound and used to rank its potency. These IC50s were compared with IC50s measured with the neutral red assay. 2-acetylaminofluorene, benzo[a]pyrene and methylnitrosourea were not cytotoxic in the neutral red assay. Uridine uptake was always inhibited at lower concentrations…

Neutral redCarcinoma Hepatocellular[SDV.TOX.TCA]Life Sciences [q-bio]/Toxicology/Toxicology and food chainToxicologyXenobiotics03 medical and health scienceschemistry.chemical_compoundInhibitory Concentration 500302 clinical medicineNeutral redToxicity TestsTumor Cells CulturedPotencyCytotoxic T cellHumansBenzopyrenesCytotoxicityColoring AgentsUridine030304 developmental biology0303 health sciencesReproducibility of ResultsMethylnitrosourea2-AcetylaminofluoreneUridine uptakeIn vitroUridineKineticschemistryBiochemistryCytotoxicity-helpG2 cell line[SDV.TOX.TCA] Life Sciences [q-bio]/Toxicology/Toxicology and food chain030220 oncology & carcinogenesisToxicityCarcinogensHepatocytesPyreneRNARegression AnalysisWater Pollutants Chemical
researchProduct

The geography of foreign news on television

2012

Since the advent of television in the middle of the 20th century, news has been an essential ingredient in TV programming. Often these newscasts are the most heavily viewed programmes, and by and large they are the main source of information for many people. This is particularly true for news from other countries and regions in the world. This immense significance of TV news has made it an important field in communication research. The article presents a new study that is formed from a multinational project. The project investigated foreign TV news in 17 countries from five regions in the world: Belgium, Brazil, Canada, Chile, China, Egypt, Germany, Hong Kong, Israel, Italy, Japan, Poland,…

News bureauGeographySociology and Political ScienceEconomyInternational communicationContent analysisMultinational corporationCommunicationChinaField (geography)International Communication Gazette
researchProduct

Hepatectomy Versus Sorafenib in Advanced Non-Metastatic Hepatocellular Carcinoma: A Real-Life Multicentric Weighted Comparison

2022

Objective: The aim of the study was to compare SURG vs SOR regarding the OS and progression-free survival (PFS) in a real-world clinical scenario. Background data: The treatment for advanced nonmetastatic HCC belonging to the Barcelona Clinic Liver Cancer stage C (BCLC C) is still controversial. Methods: BCLC C patients without extrahepatic spread and tumoral invasion of the main portal trunk were considered. Surgical patients were obtained from the HE.RC.O.LE.S. Register, whereas sorafenib patients were obtained from the ITA.LI.CA register The inverse probability weighting (IPW) method was adopted to balance the confounders between the 2 groups. Results: Between 2008 and 2019, 478 patients…

NiacinamideCarcinoma HepatocellularHepatocellular carcinomahepatocellular carcinoma surgery sorafenib bclcPhenylurea CompoundsCarcinomaSettore MED/09 - MEDICINA INTERNALiver Neoplasmsadvanced HCCHepatocellularAntineoplastic Agentssystemic therapies.SorafenibBCLC CNOTreatment Outcomesystemic therapiesmacrovascular invasionHumansHepatectomySurgeryHepatectomy; Humans; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome; Antineoplastic Agents; Carcinoma Hepatocellular; Liver NeoplasmsLiver surgeryNeoplasm StagingRetrospective Studies
researchProduct

Nanoassemblies Based on Supramolecular Complexes of Nonionic Amphiphilic Cyclodextrin and Sorafenib as Effective Weapons to Kill Human HCC Cells

2015

Sorafenib (Sor), an effective chemiotherapeutic drug utilized against hepatocellular carcinoma (HOC), robustly interacts with nonionic amphiphilic cyclodextrin (aCD, SC6OH), forming, in aqueous solution, supramolecular complexes that behave as building blocks of highly water-dispersible colloidal nanoassemblies. SC6OH/Sor complex has been characterized by complementary spectroscopic techniques, such as UV-vis, steady-state fluorescence and anisotropy, resonance light scattering and H-1 NMR. The spectroscopic evidences and experiments carried out in the presence of an adamantane derivative, which competes with drug for CD cavity, agree with the entrapment of Sor in aCD, pointing out the role…

NiacinamideErythrocytesPolymers and PlasticsCell SurvivalAdamantaneDrug CompoundingSupramolecular chemistryBioengineeringNanotechnologyAdamantaneAntineoplastic AgentsBinding CompetitiveHemolysisAmphiphilic Cyclodextrins; Nanoparticles; Sorafenib; HCC cellsHCC cellsBiomaterialschemistry.chemical_compoundSurface-Active AgentsIn vivoCell Line TumorAmphiphileMaterials ChemistryHumanschemistry.chemical_classificationCyclodextrinsAqueous solutionCyclodextrinPhenylurea CompoundsSorafenibFluorescenceCombinatorial chemistrydigestive system diseasesNanostructuresBINDING INTERACTION THERAPY PHARMACOKINETICS BIOAVAILABILITY NANOPARTICLESDrug LiberationKineticsnanoassembliecyclodextrinchemistryDelayed-Action PreparationsProton NMRHepatocytes
researchProduct

Transarterial chemoembolization and sorafenib in hepatocellular carcinoma

2014

Transarterial chemoembolization (TACE) is considered as the standard therapy for patients with intermediate-stage hepatocellular carcinoma. However, given the high heterogeneity of this population, no common strategy or protocol standardization has been defined yet. In the last few years TACE treatment has been combined with sorafenib systemic therapy, reporting overall positive results both in terms of safety and efficacy. This systematic review presents and critically discusses the evidence available on the use of TACE in combination (concomitant or sequential) with sorafenib, focusing also on clinical trials currently ongoing to better define an optimal therapeutic strategy for this grou…

NiacinamideOncologySorafenibmedicine.medical_specialtyCarcinoma HepatocellularCombination therapyPopulationAntineoplastic AgentsSystemic therapyInternal medicinemedicineHumansPharmacology (medical)Chemoembolization TherapeuticeducationTherapeutic strategyClinical Trials as Topiceducation.field_of_studybusiness.industryPhenylurea CompoundsLiver NeoplasmsSorafenibmedicine.diseaseClinical trialOncologyHepatocellular carcinomaConcomitantRadiologybusinessmedicine.drugExpert Review of Anticancer Therapy
researchProduct

Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?

2013

Cancer is a prevalent disease in the elderly population and hepatocellular carcinoma (HCC) is a major health problem among all tumors. Curative treatments for early-stage include liver transplantation, resection and percutaneous ablation. Transarterial chemoembolization (TACE) and sorafenib, classified as non-curative treatments, can improve survival for patients with intermediate and advanced tumors, respectively. Even if the incidence of HCC progressively increases with advanced age in all populations, reaching a peak at 70 years, few reports concerning correct management of HCC in elderly patients exist. Moreover, data from large randomized controlled trials (RCT) poorly reflect the elde…

NiacinamideOncologySorafenibmedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentAntineoplastic AgentsDiseaseLiver transplantationSystemic therapylaw.inventionRandomized controlled triallawInternal medicinemedicineHumansPharmacology (medical)HCCAgedbusiness.industryPhenylurea CompoundsIncidence (epidemiology)Liver NeoplasmsAge FactorsCancerSorafenibmedicine.diseasedigestive system diseasesOncologyHepatocellular carcinomabusinessmedicine.drugExpert Review of Anticancer Therapy
researchProduct

Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions

2013

The intermediate stage of hepatocellular carcinoma (HCC) comprises a highly heterogeneous patient population and therefore poses unique challenges for therapeutic management, different from the early and advanced stages. Patients classified as having intermediate HCC by the Barcelona Clinic Liver Cancer (BCLC) staging system present with varying tumor burden and liver function. Transarterial chemoembolization (TACE) is currently recommended as the standard of care in this setting, but there is considerable variation in the clinical benefit patients derive from this treatment.In April 2012, a panel of experts convened to discuss unresolved issues surrounding the application of current guidel…

NiacinamideOncologymedicine.medical_specialtyCarcinoma HepatocellularStandard of careTumor burdenAntineoplastic AgentsGastroenterologyAntineoplastic AgentInternal medicinemedicineHumansChemoembolization TherapeuticStaging systemHepatologybusiness.industryPhenylurea CompoundsLiver NeoplasmsAdvanced stageSorafenibmedicine.diseasedigestive system diseasesLiver NeoplasmHepatocellular carcinomaLiver functionTreatment decision makingLiver cancerbusinessHumanSeminars in Liver Disease
researchProduct

Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis

2014

Background: Data on survival and safety of sorafenib for hepatocellular carcinoma recurrence after liver transplant are still equivocal. Aim: We performed a meta-analysis of published studies, with the aim of estimating the 1-year rates of survival, analysing the variability in survival rates and, finally, identifying the factors associated with a longer survival. Methods: Data from 8 of the 17 selected studies were pooled, while the other 9 were excluded because survival rates were missing. All included studies were retrospective. Results: Overall, the 1-year survival ranged from 18% to 90%. Tumour progression was the main cause of death. The second cause was bleeding, reported only in pat…

NiacinamidePhenylurea CompoundOncologySorafenibmedicine.medical_specialtyCarcinoma HepatocellularHepatocellular carcinomamedicine.medical_treatmentAntineoplastic AgentsLiver transplantationAntineoplastic AgentRecurrenceInternal medicinemedicineHumansIn patientPostoperative PeriodProspective cohort studyLiver transplantSurvival rateCause of deathHepatologybusiness.industryPhenylurea CompoundsLiver NeoplasmsGastroenterologySorafenibmedicine.diseaseLiver TransplantationSurvival RateReceptors Vascular Endothelial Growth FactorLiver NeoplasmHepatocellular carcinomaMeta-analysisNeoplasm Recurrence LocalbusinessHumanmedicine.drugDigestive and Liver Disease
researchProduct

Extrahepatic spread of hepatocellular carcinoma

2012

Hepatocellular carcinoma (HCC) is a major health problem. The treatment of HCC depends on the tumour stage and on the severity of underlying cirrhosis, however, a majority of HCC patients have advanced disease at presentation. In recent years extra-hepatic spread (ES) of HCC seems to have been observed more frequently than in the past even if few data exist in literature on prevalence, clinical presentation and prognosis of patients with HCC ES. Aim of this brief review is underline the main concerns, pitfalls and warnings in practicing with these patients. ES of HCC are not rare, and the probability of finding ES is higher in patients with advanced intra-hepatic HCC. The more frequent ES s…

NiacinamideSettore MED/12 - GastroenterologiaCarcinoma HepatocellularPhenylurea CompoundsLiver NeoplasmsCarcinomaCarcinoma; Hepatocellular; Neoplasm metastasis; sorafenibAntineoplastic AgentsHepatocellularPrognosisSettore MED/28 - Malattie OdontostomatologicheAnimalsHumansNeoplasm InvasivenesssorafenibMolecular Targeted TherapyProtein Kinase InhibitorsNeoplasm metastasi
researchProduct